Sex: U
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Fatigue, Headache, Malaise
Clinical narrative: Intense general malaise/feeling of being sick with significant interference in activity; Significant pain at the injection site that prevented daily activity; Mild swelling at the injection site; Mild fever (100.4 to 101.2 °F)/38.0 to 38.4 °C) ; Severe fatigue with significant interference in activity; Moderate muscle pain with some interference in activity.; Joint pain with some interference in activity; Headache that prevented daily activity OR required the use of an over-the-counter pain reliever; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Intense general malaise/feeling of being sick with significant interference in activity), VACCINATION SITE PAIN (Significant pain at the injection site that prevented daily activity), VACCINATION SITE SWELLING (Mild swelling at the injection site), PYREXIA (Mild fever (100.4 to 101.2 °F)/38.0 to 38.4 °C) ) and FATIGUE (Severe fatigue with significant interference in activity) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Intense general malaise/feeling of being sick with significant interference in activity), VACCINATION SITE PAIN (Significant pain at the injection site that prevented daily activity), VACCINATION SITE SWELLING (Mild swelling at the injection site), PYREXIA (Mild fever (100.4 to 101.2 °F)/38.0 to 38.4 °C) ), FATIGUE (Severe fatigue with significant interference in activity), MYALGIA (Moderate muscle pain with some interference in activity.), ARTHRALGIA (Joint pain with some interference in activity) and HEADACHE (Headache that prevented daily activity OR required the use of an over-the-counter pain reliever). At the time of the report, MALAISE (Intense general malaise/feeling of being sick with significant interference in activity), VACCINATION SITE PAIN (Significant pain at the injection site that prevented daily activity), VACCINATION SITE SWELLING (Mild swelling at the injection site), PYREXIA (Mild fever (100.4 to 101.2 °F)/38.0 to 38.4 °C) ), FATIGUE (Severe fatigue with significant interference in activity), MYALGIA (Moderate muscle pain with some interference in activity.), ARTHRALGIA (Joint pain with some interference in activity) and HEADACHE (Headache that prevented daily activity OR required the use of an over-the-counter pain reliever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F)/38.0 to 38.4 °C).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Database Subject ID was reported as 5472419 and Health Authority ID was reported as 41434-53116.  No concomitant medications were reported.  The patient had experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred on Thursday, Dec 21, 2023 and Friday, Dec 22, 2023.  No treatment information was provided.